Genenta Science SpA ADR

Genenta Science SpA ADR FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Genenta Science SpA ADR (GNTA) as of Oct 27, 2026 is 109.62 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 67.08 % — a change of 63.43% (higher).

FCF Conversion

109.62 %

YoY

63.43%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Genenta Science SpA ADR is 2025 109.62 % . FCF Conversion Rate (FCF/EBITDA) of Genenta Science SpA ADR was 2024 67.08 % . It decreases by 63.43% higher compared to the previous year.

The Genenta Science SpA ADR FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
55.40 USD
Jan 1, 2020
116.56 USD
Jan 1, 2021
120.87 USD
Jan 1, 2022
89.92 USD
Jan 1, 2023
98.06 USD
Jan 1, 2024
67.08 USD
Jan 1, 2025
109.62 USD
The Genenta Science SpA ADR FCF Conversion history
YEARFCF ConversionYoY
109.62 %+63.43%
67.08 %-31.60%
98.06 %+9.05%
89.92 %-25.61%
120.87 %+3.70%
116.56 %+110.40%
55.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genenta Science SpA ADR Stock analysis

What does Genenta Science SpA ADR do? Genenta Science S.p.A. generates value by developing hematopoietic stem cell gene therapies for solid tumors in Italy. The company focuses on its product Temferon, which is currently in Phase 1/2a clinical trials for the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. Additionally, the firm is expanding the application of Temferon to other solid tumor indications. The business model relies on a proprietary biologic platform designed to deliver immunomodulatory molecules directly to tumors by infiltrating monocytes and macrophages. As a clinical-stage biotechnology company incorporated in 2014 and headquartered in Milan, Italy, Genenta Science S.p.A. utilizes this platform to advance its therapeutic pipeline and address unmet medical needs in oncology. Genenta Science SpA ADR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genenta Science SpA ADR stock

FCF Conversion Rate (FCF/EBITDA) of Genenta Science SpA ADR is 109.62 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Genenta Science SpA ADR changed from 67.08 % to 109.62 %, representing a 63.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Genenta Science SpA ADR since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Genenta Science SpA ADR with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Genenta Science SpA ADR

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Genenta Science SpA ADR